Plant Name: Lepidium draba
Taxonomic Information:
Plant ID: NPO5510
Plant Latin Name: Lepidium draba
Taxonomy Genus: Lepidium
Taxonomy Family: Brassicaceae
Plant External Links:
NCBI TaxonomyDB:
153317
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
China; India; TurkmenistanTraditional Medicine System:
Indian Folk; TCMGeographical Distribution:
India; China; Turkmenistan
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| BLM; ALPL; RECQL; ALOX12; HSD17B2; HSD17B10; NOX4; POLB; | |
| MET; FLT3; CDK1; PIM1; AXL; KDR; IGF1R; AURKB; | |
| CA2; CA12; CA7; | |
| RORC; | |
| NR1H4; | |
| TYR; | |
| AHR; NFKB1; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 8.862E-09 | 1.961E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.704E-08 | 6.402E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 6.014E-08 | 6.892E-05 | ALPL, BLM, CYP1A1, CYP1B1, FLT3, NFKB1, NOX4, RORC |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.457E-07 | 3.033E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 4.904E-07 | 3.236E-04 | AXL, BLM, CA2, CDK1, CYP1A1, CYP1A2, CYP1B1, KDR |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 5.317E-07 | 3.405E-04 | ALOX12, AURKB, AXL, CDK1, IGF1R, KDR, LMNA, NFKB1, NR1H4, PIM1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.681E-06 | 8.512E-04 | CA12, CA2, CA7 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.748E-06 | 8.628E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 4.488E-06 | 1.844E-03 | ALPL, AXL, CYP1A1, CYP1A2, NFKB1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.881E-06 | 1.933E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.229E-06 | 1.998E-03 | ALOX12, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 6.486E-06 | 2.306E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 7.471E-06 | 2.503E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 7.471E-06 | 2.503E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 1.088E-05 | 3.384E-03 | AXL, FLT3, IGF1R, KDR, MET |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 1.401E-05 | 4.063E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.493E-05 | 4.063E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.493E-05 | 4.063E-03 | CYP1A2, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0009628; response to abiotic stimulus | 1.938E-05 | 4.966E-03 | AURKB, BLM, CA2, CYP1A1, LMNA, NFKB1, NOX4, POLB, TYR |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.485E-05 | 5.843E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 2.485E-05 | 5.843E-03 | BLM, RECQL |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.578E-05 | 5.933E-03 | CA12, CA2, CA7 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 3.088E-05 | 6.724E-03 | AURKB, CDK1, CYP1A1, NOX4, POLB |
| BP | GO:0008152; metabolic process | GO:0010557; positive regulation of macromolecule biosynthetic process | 3.153E-05 | 6.799E-03 | AHR, AURKB, BLM, CDK1, IGF1R, KDR, MET, NFKB1, NOX4, NR1H4, RORC |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 3.362E-05 | 7.176E-03 | BLM, IGF1R, NFKB1, NOX4, NR1H4, TSHR |
| MF | GO:0060089; molecular transducer activity | GO:0038023; signaling receptor activity | 3.636E-05 | 7.686E-03 | AHR, AXL, FLT3, IGF1R, KDR, MET, NPSR1, NR1H4, RORC, TSHR |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 3.724E-05 | 7.723E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.724E-05 | 7.723E-03 | CYP1A2, CYP3A4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.741E-05 | 9.300E-03 | CA12, CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 5.209E-05 | 9.862E-03 | CYP1A2, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 5.209E-05 | 9.862E-03 | FLT3, KDR |
| MF | GO:0003824; catalytic activity | GO:0043140; ATP-dependent 3'-5' DNA helicase activity | 5.209E-05 | 9.862E-03 | BLM, RECQL |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.758E-08 | 3.144E-06 | CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.035E-06 | 5.897E-05 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.769E-06 | 1.359E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 7.590E-06 | 1.731E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 3.204E-05 | 6.088E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.259E-06 | 8.585E-05 | CA12, CA2, CA7 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 9.322E-05 | 1.518E-03 | FLT3, PIM1, NFKB1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.380E-04 | 1.966E-03 | CYP1A2, CYP1A1, CYP3A4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 3.997E-04 | 4.143E-03 | KDR, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.651E-04 | 2.046E-03 | FLT3, MET, NFKB1, IGF1R |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 4.640E-04 | 4.408E-03 | HSD17B2, CYP1A2, CYP1A1, ALPL, ALOX12, CYP3A4, TYR, HSD17B10 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.794E-04 | 2.046E-03 | CA2, NR1H4, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.093E-03 | 8.900E-03 | PIM1, CYP1B1, MET, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 9.197E-04 | 8.065E-03 | CYP1A2, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| NA: NA | GIST | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| NA: NA | HIV infections | NA | AHR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | TYR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
